I Want To Make A Grand Entrance With The DS N°8Color Temperature Meters Market Insights: In-Depth Analysis of Key Players and Market Dynamics 11-23-2024 12:37 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Valuates Reports Color Temperature Meters Market Size The global Color Temperature Meters market was valued at US$ 284 million in 2023 and is anticipated to reach US$ 486.7 million by 2030, witnessing a CAGR of 8.0% during the forecast period 2024-2030. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-15A16863/Global_Color_Temperature_Meters_Market_Research_Report_2024 Major Trends The global color temperature meters market is growing steadily, driven by increasing demand from industries like photography, cinematography, and lighting design. These meters are essential for measuring and calibrating light sources to ensure consistent and accurate color reproduction. The growing adoption of LED lighting, which requires precise color temperature adjustments, is a key driver for market growth. Furthermore, advancements in digital imaging and the need for high-quality visual content are spurring demand for these devices across professional and industrial applications. Trends Influencing the Growth of the Global Color Temperature Meters Market A notable trend in the color temperature meters market is the adoption of handheld and portable devices. Professionals in photography and cinematography increasingly prefer lightweight and compact meters for on-the-go use, allowing for quick adjustments in dynamic environments. This portability trend is driving innovation, with manufacturers focusing on ergonomic designs and user-friendly interfaces. The integration of smart technologies, such as Bluetooth and app connectivity, is revolutionizing the functionality of color temperature meters. These features allow users to control and analyze data remotely via smartphones or tablets, enhancing operational efficiency. This trend reflects the growing demand for digital solutions in professional lighting setups. Customization and industry-specific applications of color temperature meters are also gaining traction. For instance, meters designed specifically for horticultural lighting are being developed to optimize plant growth by ensuring the right spectrum of light. This diversification highlights the expanding use of these devices beyond traditional industries. Lastly, the increasing adoption of LED and energy-efficient lighting solutions is boosting the demand for color temperature meters. As LEDs become the standard in residential, commercial, and industrial lighting, accurate color temperature measurement is critical for achieving desired lighting effects and ensuring consistency across various settings. Purchase Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-15A16863/Global_Color_Temperature_Meters_Market_Research_Report_2024 Color Temperature Meters Market Share The market for color temperature meters is distributed across regions, with North America and Europe leading due to advanced industries in cinematography and lighting design. Asia-Pacific is emerging as a significant growth region, driven by increased adoption of energy-efficient lighting and expanding digital media industries. By Type •Industrial Grade Color Temperature Meters •Research Grade Color Temperature Meters By Application •Photography Studios •Architectural Lighting Design •Environmental Monitoring •Scientific Research and Education Key Companies Konica Minolta Sensing Americas, Inc., Sekonic Corporation, X-Rite, Incorporated, Dr. Meter, Klein Tools, Testo SE & Co. KGaA, REED Instruments, Hioki E.E. Corporation, Tenmars Electronics Co., Ltd., UPRtek, Hagner AB, Solartech Inc., TES Electrical Electronic Corp., Konus S.p.A., ETI Ltd. (Electronic Temperature Instruments Ltd.) View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-15A16863/global-color-temperature-meters Please reach us at sales@valuates.com Address: Valuates, 4th Floor, Balaraj's Arcade, Whitefield Main road, Bangalore 560066 Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends. This release was published on openPR.Florida knocks No. 9 Ole Miss out of College Football Playoff contention
The world approved a bitterly negotiated climate deal Sunday committing wealthy historic polluters to $300 billion annually for poor and vulnerable nations that had demanded far more to confront the crisis of global warming. After two exhaustive weeks of chaotic bargaining and sleepless nights, nearly 200 nations banged through the contentious finance pact in the early hours beneath a sports stadium roof in Azerbaijan. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.NEW YORK (AP) — An early rebound for U.S. stocks petered out by the end of the day, leaving indexes close to flat. The S&P 500 edged down by 0.1% Thursday, coming off one of its worst days of the year after the Federal Reserve said it may deliver fewer cuts to interest rates in 2025 than earlier thought. The Dow Jones Industrial Average inched up by less than 0.1%, and the Nasdaq composite slipped 0.1%. Treasury yields were mixed in the bond market following reports showing the U.S. economy may be stronger than expected, but manufacturing may be contracting again. THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below. NEW YORK (AP) — U.S. stocks are stabilizing Thursday following one of their worst days of the year . The S&P 500 rose 0.2% in late trading, a day after tumbling 2.9% when the Federal Reserve said it may deliver fewer cuts to interest rates next year than earlier thought. The Dow Jones Industrial Average was up 136 points, or 0.3%, with less than an hour remaining in trading, following Wednesday’s drop of more than 1,100 points. The Nasdaq composite rose 0.3%. Wednesday’s drop took some of the enthusiasm out of the market, which critics had already been warning was overly buoyant and would need everything to go correctly for it to justify its high prices. But indexes remain near their records , and the S&P 500 is still on track for one of its best years of the millennium . Traders are now expecting the Federal Reserve to deliver just one or maybe two cuts to interest rates next year, according to data from CME Group. Some are even betting on none. A month ago, the majority saw at least two cuts in 2025 as a safe bet. Wall Street loves lower interest rates because they give the economy a boost and goose prices for investments, but they can also provide fuel for inflation. Darden Restaurants, the company behind Olive Garden and other chains, helped lift the market after leaping 15.1%. It delivered profit for the latest quarter that edged past analysts’ expectations. The operator of LongHorn Steakhouses also gave a forecast for revenue for this fiscal year that topped analysts’. Accenture rose 6.7% after the professional services company likewise topped expectations for profit in the latest quarter. CEO Julie Sweet said it saw growth around the world, and the company raised its forecast for revenue this fiscal year. Amazon shares added 1.8%, even as workers at seven of its facilities went on strike Thursday in the middle of the online retail giant’s busiest time of the year. Amazon says it doesn’t expect an impact on its operations during what the workers’ union calls the largest strike against the company in U.S. history. They helped offset a tumble for Micron Technology, which fell 16.7% despite reporting stronger profit than expected. The computer memory company’s revenue fell short of Wall Street’s forecasts, and CEO Sanjay Mehrotra said it expects demand from consumers to remain weaker in the near term. It gave a forecast for revenue in the current quarter that fell well short of what analysts were thinking. Lamb Weston, which makes French fries and other potato products, dropped 22.6% after falling short of analysts’ expectations for profit and revenue in the latest quarter. It also cut its financial targets for the fiscal year, saying demand for frozen potatoes is continuing to soften, particularly outside North America. The company replaced its chief executive. In the bond market, yields were mixed a day after shooting higher on expectations that the Fed would deliver fewer cuts to rates in 2025. Reports on the U.S. economy came in mixed. One showed the overall economy grew at a 3.1% annualized rate during the summer, faster than earlier thought. The economy has remained remarkably resilient even though the Fed held its main interest rate at a two-decade high for a while before beginning to cut them in September. A separate report showed fewer U.S. workers applied for unemployment benefits last week, an indication that the job market also remains solid. But a third report said manufacturing in the mid-Atlantic region is unexpectedly contracting again despite economists’ expectations for growth. The yield on the 10-year Treasury rose to 4.57% from 4.52% late Wednesday and from less than 4.20% earlier this month. But the two-year yield, which more closely tracks expectations for action by the Fed in the near term, eased back to 4.31% from 4.35%. The rise in longer-term yields has put pressure on the housing market by keeping mortgage rates higher. Homebuilder Lennar fell 4.8% after it reported weaker profit and revenue for the latest quarter than analysts expected. CEO Stuart Miller said that “the housing market that appeared to be improving as the Fed cut short-term interest rates, proved to be far more challenging as mortgage rates rose” through the quarter. “Even while demand remained strong, and the chronic supply shortage continued to drive the market, our results were driven by affordability limitations from higher interest rates,” he said. A report on Thursday may have offered some encouragement for the housing industry. It showed a pickup in sales of previously occupied homes. In stock markets abroad, London’s FTSE 100 fell 1.1% after the Bank of England paused its cuts to rates and kept its main interest rate unchanged on Thursday. The move comes as inflation there moved further above the central bank’s 2% target rate, while the British economy is flatlining at best. The Bank of Japan also kept its benchmark interest rate unchanged, and Tokyo’s Nikkei 225 fell 0.7%. Indexes likewise sank across much of the rest of Asia and Europe. ___ AP Business Writers Matt Ott and Elaine Kurtenbach contributed. Stan Choe, The Associated PressAadi Enters Agreement to Sell FYARRO ® and Associated Infrastructure to KAKEN Pharmaceutical for $100M ; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. ( HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million , cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million , before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon , PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. PTK7-CPT113 potentially represents a differentiated opportunity to be among the first next-wave ADCs in clinical development for high PTK7 expressing cancers, including non-small cell lung cancer (NSCLC), ovarian cancer and several other major indications. mMUC16-CPT113 is the first ADC that targets membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. biSEZ6-CPT113 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin. biSEZ6-CPT113 utilizes a dual epitope binding, or biparatopic, approach which can potentially improve internalization and effectiveness of the ADC. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen , CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." " HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China ," said Dr. Robert Y. Zhao , President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million , Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan , has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO ® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024 . Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024 . Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein , MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20 th at 8:00 AM EST ( 5:00 AM PST ) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio.com . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at www.sec.gov , as well as on the Investor and News section of Aadi's website at www.aadibio.com . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024 , and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: IR@aadibio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-million-sale-of-fyarro-and-100-million-pipe-financing-302336743.html SOURCE Aadi BiosciencePORTLAND, Ore. (AP) — A businessman with no experience in public office is taking over as mayor of Oregon ’s biggest city as it embraces an entirely new system of government — one that’s so different, the City Council chambers had to be completely renovated. Portland voters last month elected Keith Wilson, a trucking company executive and founder of a nonprofit working to increase homeless shelter capacity. He ran on an ambitious pledge to end unsheltered homelessness within a year and was sworn in Thursday alongside a council expanded from five seats to 12. Portland is contending with homelessness , public drug use and a rising cost of living. Wilson, a Portland native, plans to reach his goal of ending unsheltered homelessness by increasing the number of nighttime walk-in emergency shelters in facilities such as churches and community centers. His message appeared to have resonated in a city where surveys conducted over the past few years have shown that residents view homelessness as a top issue. He ran against three outgoing City Council members. “Our city government has been reimagined, embodying the best of our innovation and values,” Wilson said on the stage of the Newmark Theater in downtown Portland after taking the oath of office. “Now it's time for Portland's new leadership to meet the moment we now face and solve the issues that prevent us from reaching our true potential.” Wilson said he will treat homelessness as a crisis. He noted the city's plans, announced earlier in the day, to open 200 overnight winter emergency shelter beds. “Tents, tarps and RVs are not places to sleep, because we will have secure shelters for everyone,” he said. The mayoral race , which featured 19 candidates, was thrown open when Mayor Ted Wheeler decided against seeking reelection after holding the city’s top post since 2017. Wheeler rose to national prominence in 2020 as nightly protests erupted on Portland streets and around the country in response to the police killing of George Floyd . The field of candidates in council races was crowded as well, with nearly 100 running for the new seats that were elected by voters in individual districts rather than citywide. READ: The new city council sworn in Thursday “is more diverse and representative than any that came before,” Wilson said. Women make up half of the new council, which also includes multiple people of color — including the first two Asian-Americans to serve on the body. The 130-year-old City Hall was renovated for $8.3 million to accommodate the increase in members. The new dais can now seat 12 people; floor layouts were changed to create more office space; and technology, seismic and accessibility updates were added throughout the building. “Remodeling council chambers is a once-in-a-generation activity,” Maty Sauter, director of Portland's Bureau of Fleet and Facilities, told the outgoing City Council as it held its last meeting on Wednesday in the new chambers. “We've been able to reuse this 1895 facility and make it modern, contemporary and useful.” It’s going to take time for the new government to figure out which of the many changes are working, said Chris Shortell, associate professor of political science at Portland State University. In another first for City Hall, Wilson and the incoming Council members were elected under Portland's new system of ranked-choice voting . A candidate would win if they were the first choice of more than 50% of voters in the first round. Otherwise, a second round would eliminate the candidate with the fewest votes and their supporters’ votes go to their next choice. The process would repeat until someone emerges with a majority of votes. Some 34% of voters ranked Wilson as their first choice, according to final results. The new City Council will hold its first meeting in January. Copyright 2024 The Associated Press . All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Stock market today: Wall Street ends little changed after giving up a big morning gain
Vikings waive former starting cornerback Akayleb Evans in another blow to 2022 draft class
Cetera Strengthens Executive Leadership to Propel Strategic Growth and InnovationA pair of teams with minimal rest will face off in Nassau, Bahamas, on Sunday when No. 22 St. John takes on Georgia. St. John's (5-1), which will play its third game in four days, began the stretch in the Bahamas Championship on Thursday, dropping a heartbreaker to No. 13 Baylor. The Red Storm led by 18 in the first half before Baylor forced overtime. From there, St. John's rallied from five down with 1:47 left to send the game to a second overtime, where it saw Baylor knock down a pair of 3-pointers in the final seven seconds -- including Jeremy Roach's buzzer-beater -- to knock off the Red Storm 99-98. In the third-place game on Friday, St. John's breezed past Virginia 80-55. RJ Luis Jr. led the way with 18 points and four steals, followed by Kadary Richmond's 12 points, as the Red Storm took a one-point lead with 15:21 left in the first half and didn't trail again. "I'm really impressed with our guys, coming off a double-overtime, extremely emotional loss," St. John's head coach Rick Pitino said. "To respond that way was extremely impressive, both offensively and defensively." Pitino, in his second year with the Red Storm, was moved by something off the court on Friday, involving captain Zuby Ejiofor, who chipped in eight points, nine boards, two steals and two blocks. Ejiofor was serenaded by St. John's fans during the win, following his two missed free throws at the end of double overtime against Baylor. "When you've only been in a job for a year, you search for things you love about a place," Pitino said. "Tonight I found out what I love about St. John's. Our fans chanted Zuby's name the whole game, which doesn't happen anywhere else in America. I was really impressed with our fans and I thank them for making Zuby feel good, because he gives you all the energy." Luis leads the Red Storm with 17.3 points per game, followed by Ejiofor (10.7), Aaron Scott (10.5), Deivon Smith (10.3) and Richmond (10.2). Georgia enters Sunday's matchup looking to rebound from its first loss after falling to No. 15 Marquette 80-69 on Saturday. Georgia (5-1) battled back from a 15-point, second-half deficit, but was held to just three points over the final 4:57 in Saturday's loss. Blue Cain led the Bulldogs with a season-high 17 points, including five 3-pointers. "It's a process. It's a journey with this team," Bulldogs head coach Mike White said. "It's about continuing to make strides, continuing to protect our culture. ... At the end of the day, wins and losses are going to take care of themselves. We just have to embrace the process and enjoy it." Five-star freshman recruit Asa Newell was held to a season-low nine points but leads the team with 15.5 points per game. Silas Demary Jr. is second with 13.8. --Field Level Media
Stock market today: Wall Street ends little changed after giving up a big morning gain
How Trump could fight California over its immigration policy